Shire (NAS: SHPG) reported earnings on Aug. 1. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Shire beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue improved and GAAP earnings per share expanded.
Gross margins expanded, operating margins shrank, net margins increased.
Shire booked revenue of $1.21 billion. The 15 analysts polled by S&P Capital IQ expected sales of $1.19 billion on the same basis. GAAP reported sales were 14% higher than the prior-year quarter's $1.06 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.68. The 14 earnings estimates compiled by S&P Capital IQ anticipated $1.52 per share. GAAP EPS of $0.41 for Q2 were 14% higher than the prior-year quarter's $0.36 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 87.4%, 90 basis points better than the prior-year quarter. Operating margin was 25.3%, 310 basis points worse than the prior-year quarter. Net margin was 19.7%, 40 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $1.16 billion. On the bottom line, the average EPS estimate is $1.47.
Next year's average estimate for revenue is $4.72 billion. The average EPS estimate is $6.02.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 120 members out of 140 rating the stock outperform, and 20 members rating it underperform. Among 44 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 33 give Shire a green thumbs-up, and 11 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Shire is outperform, with an average price target of $103.41.
The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Shire the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
Add Shire to My Watchlist.
The article Shire Beats on Both Top and Bottom Lines originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.